BDron 500 mg contains Abiraterone Acetate, a targeted oral therapy used in the treatment of advanced prostate cancer. It is specifically indicated for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Abiraterone represents a significant step forward in prostate cancer management by targeting hormone production, one of the key drivers of the disease. It is generally prescribed along with prednisone to reduce certain side effects associated with hormonal changes.

Mechanism of Action

Abiraterone acetate is a prodrug that gets converted in the body to abiraterone, its active form. It works by:

• Inhibiting CYP17A1, an enzyme critical for the production of androgens (male hormones) in the adrenal glands, testes, and even within prostate tumors.

• Since androgens fuel prostate cancer growth, blocking their production effectively starves cancer cells of the hormones they need to survive and spread.

  Uses / Indications

  BDron 500 mg is indicated for:

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    – In patients whose cancer continues to progress despite surgical or chemical castration.

  • Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC)
    – Often combined with androgen deprivation therapy (ADT) and prednisone.

    Adverse Effects

    While BDron is generally well tolerated and effective, it may produce side effects due to the suppression of hormone synthesis.

    Common Side Effects:

    • Fatigue or weakness

    • Joint or muscle pain

    • High blood pressure (hypertension)

    • Fluid retention (swelling in legs/feet)

    • Low blood potassium (hypokalemia)